<DOC>
	<DOCNO>NCT02362178</DOCNO>
	<brief_summary>Blood product commonly use invasive procedure patient end-stage liver diseases despite cirrhosis thrombophylic state . Traditional coagulation test ( namely INR PLTs count ) know unreliable predict bleed risk invasive procedure represent real coagulation status cirrhotic patient . Notwithstanding still use guide blood product administration invasive procedure . Thromboelastography ( TEG ) show effective detecting sign hypo-hypercoagulability possibly alternative method guide blood product transfusion . The aim randomize control study evaluate efficacy TEG guide blood product transfusion cirrhotic patient undergo invasive procedure .</brief_summary>
	<brief_title>Thromboelastographic Guide Blood Products Cirrhotics</brief_title>
	<detailed_description />
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>Histologic imagingproven liver cirrhosis etiology INR &gt; 1.8 and/or PLTs count &lt; 50x103/Î¼l Ongoing bleed Previous current thrombotic event define document blood clot venous arterial vessel Ongoing antiplatelet anticoagulant therapy stop less 7 day evaluation study Presence sepsis accord ACPSCCP criterion Hemodialysis perform within 7 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>